Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA
- Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations
Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULDOSA (Project Name: DMB-3115, Active Ingredient: Ustekinumab), has received marketing authorization from the European Commission (EC) as of December 18.
This landmark approval comes just two months after the Committee for Medicinal Products for Human Use (CHMP) under the European Medicine Agency (EMA) recommended the product for approval in October. Combined with its successful U.S. Food and Drug Administration (FDA) approval in October, IMULDOSA is now fully authorized to enter the global market.
IMULDOSA, a biosimilar referencing Stelara of Janssen Pharmaceuticals, is indicated for treating inflammatory diseases, including plaque psoriasis, psoriatic arthritis, and Crohn’s disease.
Stelara, with its active ingredient ustekinumab, is among the top-grossing biologics worldwide, generating $20.323 billion in cumulative global sales in 2023, according to IQVIA.
The development of IMULDOSA began in 2013 as a joint project between Dong-A Socio Holdings and Meiji Seika Pharma. In July 2020, the development and commercialization rights held by Dong-A Socio Holdings were transferred to Dong-A ST to ensure the efficient execution of the global project. Since then, Dong-A ST and Meiji Seika Pharma have continuously collaborated to develop it.
In July 2021, Dong-A ST signed a global out-licensing agreement with multinational pharmaceutical company Intas Pharmaceuticals for IMULDOSA. Through Intas and its subsidiaries, including Accord Biopharma in the United States and Accord Healthcare in Europe, the UK, and Canada, IMULDOSA is set to be launched in multiple regions.
A representative for Dong-A ST commented, “With the consecutive approvals in the United States and Europe, IMULDOSA is now one step closer to entering the global pharmaceutical market. We will continue to dedicate our efforts to ensure that IMULDOSA establishes a strong presence in the market, providing an effective treatment option to patients worldwide.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219254328/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces $40,000 Academic Award to Empower the Next Generation of Supply Chain Innovators19.12.2024 13:00:00 CET | Press release
Company gives aspiring supply chain students a boost in honor of its 40th anniversary In celebration of its 40th anniversary, Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced a $40,000 academic award to help students looking to pursue careers in supply chain. Kinaxis is strengthening its partnerships with Texas Christian University, University of Toronto and Carleton University to provide each institution with a portion of the award to go towards helping students currently enrolled in supply chain, AI or computer science programs to shape the future of supply chains. The Kinaxis academic award comes at a time when the need for supply chain talent is growing. As validated by a recent IDC survey sponsored by Kinaxis, over 32% of global supply chain leaders stating the ability to attract and retain top talent with the right skills is a top concern for business continuity. “As supply chains increase in scale and complexity, cultivating the next
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy19.12.2024 12:00:00 CET | Press release
– Treatment with the highly selective NaV1.8 pain signal inhibitor suzetrigine met the primary endpoint with a statistically significant and clinically meaningful 2.02 point within-group reduction from baseline in the Numeric Pain Rating Scale (NPRS) –– Placebo arm showed similar within-group reduction in NPRS – – Suzetrigine was generally well tolerated –– Advancement to Phase 3 inpainful lumbosacral radiculopathy planned, pending discussions with regulators – – Vertex to host investor call on December 19 at 8:00 a.m. ET – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR). The study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (NPRS). Efficacy Results The study’s primary endpoint was a within-group change from
Ukraine Conflict Impacting Nordics Cloud Adoption19.12.2024 10:00:00 CET | Press release
Supply chain disruptions and skilled labor shortages are intensifying enterprise demands for better business value in the short term, ISG Provider Lens™ report says The conflict in Ukraine has intensified supply chain disruptions, affecting IT investments across the Nordics, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2024 ISG Provider Lens™ Multi Public Cloud Services report for the Nordics finds companies in the region are grappling with rising IT costs and a shortage of skilled labor, which is directly impacting their cloud adoption strategies. As a result, many organizations are focusing their investments on projects the deliver immediate business value, while deferring less critical initiatives. This trend, ISG says, underscores the need for agile and efficient cloud solutions that can adapt to evolving market conditions. The demand for hybrid and multicloud soluti
ASTRA 1P Starts Delivering Content Across Europe19.12.2024 08:50:00 CET | Press release
Most powerful satellite to operate at SES’s prime TV neighbourhood of 19.2 degrees East will deliver content to 118 million TV homes SES announced today that ASTRA 1P, the company's most advanced satellite positioned at 19.2 degrees East, has completed comprehensive testing and is now fully operational. Following its successful in-orbit raising and performance testing, ASTRA 1P will now start serving public and private broadcasters, sports organisations and content owners, achieving another milestone in SES’s commitment to delivering high-quality broadcast services to the widest audience possible. ASTRA 1P is SES’s most powerful wide-beam satellite to broadcast from the 19.2 degrees East TV neighbourhood. Equipped with 80 transponders, ASTRA 1P can support hundreds of HD TV channels, ensuring the delivery of superior image quality to viewers across key European TV markets. “With ASTRA 1P now fully operational, we are setting a new standard for satellite broadcasting in Europe,” said Mi
Thales to Enhance Vehicle Access With Reliable and Secure Contactless Solutions19.12.2024 08:00:00 CET | Press release
Car industry players can rely on Thales to provide digital and physical solutions that improve car access experiences, while ensuring data security. Thales's offer encompasses a digital car key solution, whose implementation follows the Car Connectivity Consortium1 (CCC) standard. It is now completed by a brand-new contactless card, the Thales NFC CARd Key. The solutions enable car drivers to lock/unlock and start their vehicles using their smartphone or their card. Drawing on its 15+ years of experience in the automotive industry, Thales delivers proven on-board car solutions leveraging its connectivity and cybersecurity expertise. Thales, a global leader in advanced technologies, provides car manufacturers with safe and hassle-free solutions to expand their customers’ vehicle access experiences. The offer leverages the digital car key solution and the smart NFC CARd Key, a new cutting-edge and customisable solution. Designed to complement the digital key, this innovative NFC-based ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom